The CDC Advisory Committee on Immunization Practices (ACIP) recommends certain vaccines for adults residing in the US.1,2 The American Academy of Family Physicians has also recently published an adult immunization schedule.3 Recommendations for vaccination against COVID-19 and seasonal influenza will be reviewed separately.
TETANUS, DIPHTHERIA, AND PERTUSSIS — Vaccines containing tetanus and diphtheria toxoids (Td) without pertussis have been used as booster doses for adults, but pertussis infection can occur when vaccine-induced immunity has...
RELEASE
The FDA has approved Leqembi Iqlik, the subcutaneous (SC) formulation of the amyloid beta-directed monoclonal antibody lecanemab, for once-weekly initiation dosing in patients with Alzheimer's disease (AD). The SC formulation was previously approved only for maintenance treatment in patients who had received IV lecanemab for at least 18 months.1
CLINICAL STUDIES — FDA approval of the new SC starting regimen was based on data from substudies of the open-label CLARITY AD extension trial that found that lecanemab exposure with once-weekly subcutaneous injection was similar to that with IV administration of the drug.2
SC administration of lecanemab was associated with less frequent systemic reactions than IV administration, but severe localized reactions leading to treatment discontinuation have occurred with the SC formulation. The risk of amyloid-related imaging abnormalities with …